Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer
©2021 American Association for Cancer Research..
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease characterized by an extensive fibroinflammatory stroma, which includes abundant cancer-associated fibroblast (CAF) populations. PDAC CAFs are heterogeneous, but the nature of this heterogeneity is incompletely understood. The Hedgehog pathway functions in PDAC in a paracrine manner, with ligands secreted by cancer cells signaling to stromal cells in the microenvironment. Previous reports investigating the role of Hedgehog signaling in PDAC have been contradictory, with Hedgehog signaling alternately proposed to promote or restrict tumor growth. In light of the newly discovered CAF heterogeneity, we investigated how Hedgehog pathway inhibition reprograms the PDAC microenvironment.
EXPERIMENTAL DESIGN: We used a combination of pharmacologic inhibition, gain- and loss-of-function genetic experiments, cytometry by time-of-flight, and single-cell RNA sequencing to study the roles of Hedgehog signaling in PDAC.
RESULTS: We found that Hedgehog signaling is uniquely activated in fibroblasts and differentially elevated in myofibroblastic CAFs (myCAF) compared with inflammatory CAFs (iCAF). Sonic Hedgehog overexpression promotes tumor growth, while Hedgehog pathway inhibition with the smoothened antagonist, LDE225, impairs tumor growth. Furthermore, Hedgehog pathway inhibition reduces myCAF numbers and increases iCAF numbers, which correlates with a decrease in cytotoxic T cells and an expansion in regulatory T cells, consistent with increased immunosuppression.
CONCLUSIONS: Hedgehog pathway inhibition alters fibroblast composition and immune infiltration in the pancreatic cancer microenvironment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Clinical cancer research : an official journal of the American Association for Cancer Research - 27(2021), 7 vom: 01. Apr., Seite 2023-2037 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Hedgehog Proteins |
|---|
| Anmerkungen: |
Date Completed 09.03.2022 Date Revised 31.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1158/1078-0432.CCR-20-3715 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320573494 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320573494 | ||
| 003 | DE-627 | ||
| 005 | 20240331232411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-20-3715 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1358.xml |
| 035 | |a (DE-627)NLM320573494 | ||
| 035 | |a (NLM)33495315 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Steele, Nina G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2022 | ||
| 500 | |a Date Revised 31.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2021 American Association for Cancer Research. | ||
| 520 | |a PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease characterized by an extensive fibroinflammatory stroma, which includes abundant cancer-associated fibroblast (CAF) populations. PDAC CAFs are heterogeneous, but the nature of this heterogeneity is incompletely understood. The Hedgehog pathway functions in PDAC in a paracrine manner, with ligands secreted by cancer cells signaling to stromal cells in the microenvironment. Previous reports investigating the role of Hedgehog signaling in PDAC have been contradictory, with Hedgehog signaling alternately proposed to promote or restrict tumor growth. In light of the newly discovered CAF heterogeneity, we investigated how Hedgehog pathway inhibition reprograms the PDAC microenvironment | ||
| 520 | |a EXPERIMENTAL DESIGN: We used a combination of pharmacologic inhibition, gain- and loss-of-function genetic experiments, cytometry by time-of-flight, and single-cell RNA sequencing to study the roles of Hedgehog signaling in PDAC | ||
| 520 | |a RESULTS: We found that Hedgehog signaling is uniquely activated in fibroblasts and differentially elevated in myofibroblastic CAFs (myCAF) compared with inflammatory CAFs (iCAF). Sonic Hedgehog overexpression promotes tumor growth, while Hedgehog pathway inhibition with the smoothened antagonist, LDE225, impairs tumor growth. Furthermore, Hedgehog pathway inhibition reduces myCAF numbers and increases iCAF numbers, which correlates with a decrease in cytotoxic T cells and an expansion in regulatory T cells, consistent with increased immunosuppression | ||
| 520 | |a CONCLUSIONS: Hedgehog pathway inhibition alters fibroblast composition and immune infiltration in the pancreatic cancer microenvironment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Hedgehog Proteins |2 NLM | |
| 700 | 1 | |a Biffi, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Kemp, Samantha B |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yaqing |e verfasserin |4 aut | |
| 700 | 1 | |a Drouillard, Donovan |e verfasserin |4 aut | |
| 700 | 1 | |a Syu, LiJyun |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Oni, Tobiloba E |e verfasserin |4 aut | |
| 700 | 1 | |a Brosnan, Erin |e verfasserin |4 aut | |
| 700 | 1 | |a Elyada, Ela |e verfasserin |4 aut | |
| 700 | 1 | |a Doshi, Abhishek |e verfasserin |4 aut | |
| 700 | 1 | |a Hansma, Christa |e verfasserin |4 aut | |
| 700 | 1 | |a Espinoza, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Abbas, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a The, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Irizarry-Negron, Valerie |e verfasserin |4 aut | |
| 700 | 1 | |a Halbrook, Christopher J |e verfasserin |4 aut | |
| 700 | 1 | |a Franks, Nicole E |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffman, Megan T |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Kristee |e verfasserin |4 aut | |
| 700 | 1 | |a Carpenter, Eileen S |e verfasserin |4 aut | |
| 700 | 1 | |a Nwosu, Zeribe C |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Lima, Fatima |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Michelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Youngkyu |e verfasserin |4 aut | |
| 700 | 1 | |a Crawford, Howard C |e verfasserin |4 aut | |
| 700 | 1 | |a Lyssiotis, Costas A |e verfasserin |4 aut | |
| 700 | 1 | |a Frankel, Timothy L |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Arvind |e verfasserin |4 aut | |
| 700 | 1 | |a Bednar, Filip |e verfasserin |4 aut | |
| 700 | 1 | |a Dlugosz, Andrzej A |e verfasserin |4 aut | |
| 700 | 1 | |a Preall, Jonathan B |e verfasserin |4 aut | |
| 700 | 1 | |a Tuveson, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Benjamin L |e verfasserin |4 aut | |
| 700 | 1 | |a Pasca di Magliano, Marina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research : an official journal of the American Association for Cancer Research |d 1995 |g 27(2021), 7 vom: 01. Apr., Seite 2023-2037 |w (DE-627)NLM09444479X |x 1557-3265 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:7 |g day:01 |g month:04 |g pages:2023-2037 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1078-0432.CCR-20-3715 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 7 |b 01 |c 04 |h 2023-2037 | ||